By Jeremiah Velasquez, FNP-BC, AGACNP-BC
Founder, Steel City HRT & Weight Loss | Board-Certified Family & Acute Care Nurse Practitioner
NPI: 1841894003

Research does not support a causal link between testosterone replacement therapy (TRT) and prostate cancer. The American Urological Association issued a Grade B recommendation stating no evidence connects TRT to cancer development. The 2023 TRAVERSE trial — 5,246 men, 33-month follow-up — found no statistically significant difference in prostate cancer incidence between men receiving TRT and those receiving placebo.

You used to be the guy who showed up. The one who pushed through — whether it was a long season working outside Bozeman, pulling double shifts, or just being fully present for the people counting on you. Somewhere along the way, that changed. And when you finally worked up the nerve to ask your doctor about testosterone, you got a wall: "We can't do that — there's too much risk to the prostate."

That warning has a history. And the history is damaging.

The entire clinical fear around testosterone and prostate cancer — the reason doctors across Montana have been slow-walking men away from TRT for decades — traces back to a study from 1941. Three patients. No control group. Fourteen days of observation. The definitive claim that testosterone fuels prostate cancer rested on a single patient who had already been surgically castrated — meaning his body was operating in a fundamentally different hormonal state than any man sitting in a provider's office asking about low T.

That is the foundation of 80 years of withheld treatment. And it is time to look at what the evidence actually says.

What's Actually Keeping Montana Men Off TRT — And Why It May Be Wrong?

Your provider isn't wrong to want to protect you. The system is wrong for giving them outdated tools to do it.

Low testosterone — clinically known as hypogonadism, a condition where the testes produce insufficient testosterone to support normal physiological function — affects an estimated 10 to 40 percent of adult men, according to data published in the Journal of Clinical Endocrinology & Metabolism. Despite that prevalence, countless men in Bozeman and across Montana have been told to simply live with the symptoms.

You know what they feel like. The fog that rolls in by mid-morning. The drive that used to fuel your work, your relationships, your edge — gone. The quiet frustration of being present in body but checked out in every way that matters.

Here is what's actually happening. One: The reference ranges your doctor uses to assess testosterone were built around population averages, not physiological optimization — meaning "normal" on your lab report may still be far below what your body requires to function at its best. Two: The foundational research claiming TRT activates prostate cancer was conducted on three patients with no control group and a 14-day observation window. Three: The fear persisted not because new evidence supported it, but because no one challenged the source material until decades later.

That's not care. That's a conveyor belt running on parts that have long since expired.

Key takeaway: The prevailing caution around TRT and prostate cancer is based on a study of three patients with no control group and a 14-day observation window — not the large-scale randomized trial evidence that now exists and shows no meaningful link.

Why Did One 1941 Study Control Testosterone Medicine for 80 Years?

Here's what most people don't know: the conclusion that testosterone "feeds" prostate cancer was never tested the way we would require today. It was an observation — and the primary observation came from a patient who had already been surgically castrated.

When a man is castrated, his prostate enters a state of extreme androgen deprivation. It behaves in a fundamentally different way than the prostate of a man with low — but physiologically intact — testosterone levels. Administering testosterone to a castrated prostate and watching it respond is not a generalizable experiment. The baseline conditions are incomparable to any man considering TRT.

This biological reality is precisely what dismantled the "fuel on a fire" theory.

In 2007, Dr. Abraham Morgentaler proposed the Saturation Model — a framework that explains why the "linear thinking" of the 1941 study was always flawed. According to research published in PMC by Morgentaler and colleagues, prostate tissue, both benign and malignant, is sensitive to androgens only at very low concentrations. Androgen receptors in the prostate reach their functional saturation point at approximately 250 ng/dL of total serum testosterone. Once those receptor sites are occupied, adding more testosterone cannot elicit additional biological stimulation. There are no remaining docking stations for the hormone to activate further growth signals.

The analogy: a parking lot that holds 100 cars is full at 100. Sending 200 cars doesn't create new spaces. It just backs up traffic.

A landmark analysis of 2,967 men confirmed this clinically — PSA levels showed no correlation with testosterone concentrations in the normal range. The correlation appeared only in men with severe testosterone deficiency, which is exactly what the Saturation Model predicts.

Key takeaway: The Saturation Model — validated across multiple clinical analyses — demonstrates that prostate tissue is only androgen-sensitive near castrate-level testosterone concentrations; once above the saturation threshold of approximately 250 ng/dL, additional testosterone cannot stimulate further prostatic growth.

What Does Evidence-Based TRT Actually Look Like for Montana Men?

Here's the honest answer: if you're a man with documented low testosterone and bothersome symptoms, the evidence no longer supports blanket refusal of TRT on prostate grounds.

The 2023 TRAVERSE trial — a Phase 4, randomized, double-blind, placebo-controlled study involving 5,246 men between the ages of 45 and 80 — found no statistically significant difference in prostate cancer incidence between TRT and placebo across a mean follow-up period of 33 months, according to findings published in JAMA Network Open. High-grade prostate cancer occurred in 5 men in the testosterone group and 3 in the placebo group — a difference that failed to reach statistical significance across 14,304 person-years of follow-up. No significant differences appeared in acute urinary retention, invasive prostate procedures, or new BPH medication initiation. The American Urological Association responded with a Grade B recommendation: there is no evidence linking testosterone therapy to the development of prostate cancer.

But there's a finding that changes the entire risk conversation for men in Billings, Bozeman, and across Montana. Low testosterone is not protective against prostate cancer. According to research published in Oncology Letters, men in the lowest testosterone group had a 5.6-fold increased risk of high-grade prostate cancer and a 72.4-fold increased risk of metastatic disease at diagnosis compared to men with normal testosterone levels. The same cohort showed a 10.7-fold increased risk of prostate cancer–specific mortality. The idea that keeping testosterone low "protects" the prostate isn't just outdated — for many men, it may be precisely backward.

Effective TRT for appropriately selected candidates follows a structured protocol. Firstly, two documented morning testosterone measurements below 300 ng/dL combined with clinical symptoms consistent with hypogonadism, followed by a full baseline evaluation of PSA, health history, and symptom severity, and ending with an individualized optimization plan with monitoring intervals calibrated to each patient's risk profile. This is exactly what the science supports — and exactly what a qualified telehealth provider can deliver without you ever leaving your home.

You've got two options. You can keep accepting the 1941 answer. Or you can ask what the 2023 evidence actually says.

Key takeaway: The 2023 TRAVERSE trial (5,246 men, 33 months) found no significant increase in prostate cancer risk with TRT, while multiple studies now document that low testosterone — not high — is associated with more aggressive, high-grade prostate cancer phenotypes.

Why Are Montana Men Choosing Steel City HRT & Weight Loss for TRT?

I've been on both sides of that table. I've been the patient who got dismissed, and I've been the provider who watched men accept fatigue and cognitive decline as inevitable because a system built around volume and liability couldn't make time for nuance. That experience shapes every protocol we build at Steel City.

Steel City HRT & Weight Loss is LegitScript-certified — one of the only telehealth hormone optimization clinics serving Montana to carry that credential, which means our practices have been independently verified against current medical and legal standards. We operate completely via telehealth. No waiting room. No clinic visit. No time off work. If you're in Bozeman, Billings, or anywhere across the state, a Steel City provider is accessible.

All medications are sourced exclusively from 503a compounding pharmacies — not research-use-only compounds, not gray-market suppliers, not unverified internet sources. Our HIPAA-secure app keeps your care ongoing and accessible, not episodic and inaccessible.

As a board-certified nurse practitioner, Jeremiah Velasquez, FNP-BC, AGACNP-BC, designs every program around your actual labs and your actual goals — not a population average and not a clinical reflex built on a study that wouldn't survive peer review today. Available programs include clinical testosterone optimization (TRT), hormone replacement therapy, GLP-1 metabolic optimization, peptide therapy, and low-dose naltrexone.

Starting with labs, followed by a telehealth consult, and ending with a personalized treatment plan delivered directly to your door.

Ready to Get Started? Montana Men Can See a Provider This Week.

If you've been told you can't do TRT because of prostate concerns, that conversation deserves a second look — one grounded in current evidence, not 80-year-old case reports. Whether you're in Bozeman, Billings, or anywhere across Montana, Steel City HRT & Weight Loss provides fully telehealth testosterone optimization with no waiting room, no unanswered questions, and no compromises on clinical standard.

You've got two options. Keep accepting the fear. Or find out what your levels actually are and what the evidence actually supports.

Labs, consult, optimization — that simple.

It all starts at steelcity-trt.com.

Frequently Asked Questions

Q: Does testosterone cause prostate cancer? A: Current evidence does not support a causal link between testosterone replacement therapy (TRT) and prostate cancer development. The American Urological Association issued a Grade B recommendation stating there is no evidence connecting TRT to prostate cancer. The 2023 TRAVERSE trial — 5,246 men over a mean 33-month follow-up — found no statistically significant difference in prostate cancer incidence between TRT and placebo groups across 14,304 person-years of observation.

Q: What is the Saturation Model and why does it matter for TRT safety? A: The Saturation Model, proposed by Dr. Abraham Morgentaler in 2007, holds that prostate tissue is only sensitive to testosterone at near-castrate concentrations — approximately 250 ng/dL total serum testosterone. Once androgen receptors reach saturation at that threshold, additional testosterone cannot stimulate further prostatic growth. This model is supported by large-scale clinical data and fundamentally shifted how urologists and endocrinologists evaluate TRT-related prostate risk.

Q: Is TRT safe for men who are concerned about their prostate? A: For appropriately selected candidates — men with documented low testosterone, baseline PSA assessment, and individualized clinical monitoring — TRT is not associated with increased prostate cancer risk per current American Urological Association guidelines. Appropriate selection typically requires two morning testosterone measurements below 300 ng/dL, symptom verification, and ongoing PSA monitoring calibrated to patient risk. Every patient's clinical picture requires individualized evaluation by a qualified provider before initiating therapy.

Q: Can I get TRT in Montana without visiting a clinic? A: Yes. Fully licensed telehealth hormone clinics serving Montana — including Steel City HRT & Weight Loss — allow men in Bozeman, Billings, and across the state to access testosterone evaluation, clinical consultation, and optimization without a single in-person visit. The process involves remote lab work, a telehealth consult with a licensed nurse practitioner, and pharmacy delivery of prescribed therapy.

Q: Is low testosterone actually protective against prostate cancer? A: The evidence now points in the opposite direction. Research published in Oncology Letters found that men with low testosterone had a 5.6-fold increased risk of high-grade prostate cancer and a 72.4-fold increased risk of metastatic disease at diagnosis compared to men with normal testosterone levels. The "Low T Paradox" — where chronically low androgen environments may promote more aggressive cancer subtypes through cellular de-differentiation — has fundamentally changed how leading urologists think about hormonal risk and prostate health.

Q: Is Steel City HRT & Weight Loss available in Montana? A: Yes. Steel City HRT & Weight Loss is a fully telehealth, LegitScript-certified hormone optimization clinic licensed to serve patients throughout Montana, including Bozeman, Billings, and statewide. Patients receive remote lab evaluation, a telehealth consult with a board-certified nurse practitioner, and an individualized care plan with treatment delivered directly to their door — no clinic visit required.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed provider before beginning any hormone or weight loss therapy. Jeremiah Velasquez, FNP-BC, AGACNP-BC, is a licensed nurse practitioner. Steel City HRT & Weight Loss is a LegitScript-certified telehealth clinic.